Focus on Metastatic Colorectal Cancer: Insights and Strategies to Refine Patient Care

Table of Contents

  • Program Overview
    Focus on Metastatic Colorectal Cancer: Insights and Strategies to Refine Patient Care
    This comprehensive program gathers insight from 5 experts to improve the skills of clinicians who treat patients with metastatic CRC, featuring education enhanced by practical tools for applying new findings in the clinic. All aspects of this program are designed to complement each other, including an Interactive Treatment Decision Aid, an expert-authored module, expert commentaries, and downloadable slidesets.

Latest Content

4 of 4 Shown
  • Metastatic Colorectal Cancer: Areas of Consensus and Controversy Among Experts

    Tanios Bekaii-Saab MD, FACP - 10/31/2017
    In this commentary on the treatment of metastatic colorectal cancer, I explore areas of consensus and controversy among experts including management of MSI-high/MMR-deficient tumors, treatment of transverse primaries, management of tumors with BRAF V600E mutations, and approaches in later lines of therapy.
  • Focus on Metastatic Colorectal Cancer: An Interactive Decision Support Tool

    This interactive treatment decision aid will let you compare your choice of therapy for patients with metastatic CRC with expert recommendations from Tanios Bekaii-Saab, MD, FACP; George A. Fisher, MD, PhD; Scott Kopetz, MD, PhD, FACP; John Strickler, MD; and Alan P. Venook, MD.
    Date Posted: 10/17/2017
  • How I Manage Patients With Chemotherapy-Refractory Metastatic CRC

    John Strickler MD - 9/11/2017
    As patients progress through first-line and second-line therapy, selection of therapy becomes more complicated and nuanced. Here’s how I navigate the multiple treatment options.
  • Combination Therapy With BRAF Inhibitors: A New Frontier in BRAF-Mutant CRC

    Scott Kopetz MD, PhD, FACP - 8/14/2017 4 comments / Last Comment: 9/16/2017
    BRAF-mutated CRC has a poor prognosis and limited treatment options. Read my thoughts on how combinations with BRAF inhibitors are offering promising benefits for this challenging population.
4 of 4 Shown
Show 0 More